Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Abvc Biopharma (ABVC) over the last 10 years, with Q3 2025 value amounting to $47287.0.

  • Abvc Biopharma's Interest & Investment Income rose 683.67% to $47287.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $97404.0, marking a year-over-year decrease of 1375.14%. This contributed to the annual value of $87358.0 for FY2024, which is 5290.19% down from last year.
  • According to the latest figures from Q3 2025, Abvc Biopharma's Interest & Investment Income is $47287.0, which was up 683.67% from $19139.0 recorded in Q2 2025.
  • Abvc Biopharma's Interest & Investment Income's 5-year high stood at $60463.0 during Q4 2022, with a 5-year trough of -$29388.0 in Q4 2021.
  • Over the past 5 years, Abvc Biopharma's median Interest & Investment Income value was $39015.0 (recorded in 2022), while the average stood at $31018.4.
  • Per our database at Business Quant, Abvc Biopharma's Interest & Investment Income crashed by 19358.04% in 2021 and then surged by 41606.13% in 2022.
  • Over the past 5 years, Abvc Biopharma's Interest & Investment Income (Quarter) stood at -$29388.0 in 2021, then surged by 305.74% to $60463.0 in 2022, then crashed by 38.01% to $37483.0 in 2023, then crashed by 68.23% to $11907.0 in 2024, then skyrocketed by 297.14% to $47287.0 in 2025.
  • Its Interest & Investment Income was $47287.0 in Q3 2025, compared to $19139.0 in Q2 2025 and $19071.0 in Q1 2025.